重度哮喘靶向生物制剂的研究现状与未来趋势  

Research Status and Future Trends of Targeted Biologics for Severe Asthma

作　　者：贾晨 周素琴[2] 何君[1] 席春林 郎儒彪 陈蓉霞 王小燕 王敏娟 梅松竹 JIA Chen;ZHOU Su-qin;HE Jun;XI Chun-lin;LANG Ru-biao;CHEN Rong-xia;WANG Xiao-yan;WANG Min-juan;MEI Song-zhu(Department of Pharmacy,Minxian People's Hospital,Dingxi 748400,China;Department of Pharmacy,the Second Hospital of Lanzhou University,Lanzhou 730030,China)

机构地区：[1]岷县人民医院药剂科,定西748400 [2]兰州大学第二医院药剂科,兰州730030

出　　处：《中国合理用药探索》2024年第11期12-18,共7页Chinese Journal of Rational Drug Use

基　　金：甘肃省青年科技基金项目(21JR7RA431)。

摘　　要：哮喘是一种全球常见的气道慢性炎症性疾病,其中重度哮喘难以得到良好控制,是临床治疗面临的一大挑战。随着对重度哮喘机制和治疗研究的不断深入,靶向生物治疗已成为治疗重度哮喘的新兴治疗手段。目前获批的生物制剂主要包括抗IL-5/IL-5R单克隆抗体、抗IgE单克隆抗体、抗IL-4/13单克隆抗体、抗TSLP单克隆抗体,主要针对2型炎症为主的重度哮喘患者,已被证明是皮质类固醇的良好替代疗法,特别是在重度哮喘的管理中,可以改善患者的生活质量。本文对重度哮喘中2型炎症型哮喘的病理机制及靶向生物制剂进行全面综述,同时强调了进一步研究其发病机制和开发新的生物制剂的重要性,为临床合理用药及未来研究提供参考。Asthma is a common chronic airway inflammatory disease in the world,and severe asthma is difficult to be well controlled,which is a great challenge in clinical treatment.With the deepening of the research on the mechanism and treatment of severe asthma,targeted biotherapy has become a new therapeutic approach for the treatment of severe asthma.Currently approved biologics mainly include anti-IL-5/IL-5R monoclonal antibodies,anti-IgE monoclonal antibodies,anti-IL-4/13 monoclonal antibodies,anti-TSLP monoclonal antibodies,mainly for patients with severe asthma with predominant type 2 inflammation,and have been shown to be a good alternative to corticosteroids,especially in the management of severe asthma,which can improve the quality of life of many patients.In this article,we reviewed the pathogenesis and targeted biological agents for type 2 inflammatory severe asthma,and addressed the importance of further study on asthma pathogenesis and development of new biological agents,so as to provide reference for clinical rational drug use and future research.

关 键 词：重度哮喘 靶向治疗药物 抗IL-5/IL-5R单克隆抗体 抗IgE单克隆抗体 抗IL-4/13单克隆抗体 抗TSLP单克隆抗体 

分 类 号：R974.3[医药卫生—药品]